Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer

靶向磷脂酰丝氨酸的新型蛋白质工程药物缀合物用于治疗乳腺癌

基本信息

  • 批准号:
    10653821
  • 负责人:
  • 金额:
    $ 46.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-06-05 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

7. Project Summary/Abstract There remains an urgent, and largely unmet need for the advancement of highly selective and effective therapeutic agents for the treatment of metastatic and triple negative breast cancer. This proposal advances an innovative and promising strategy focused on the first time synthesis and evaluation of betabody-drug conjugates (BDCs), which feature engineered proteins (referred to as betabodies) that target phosphatidylserine (PS). PS is selectively exposed on the outer leaflet of the plasma membrane of cancer cells and endothelial cells in the tumor microenvironment, but is confined to the inner leaflet of the plasma membrane of normal cells. This provides an exquisite opportunity for selective targeting of potent small-molecule anticancer payloads (KGP18 and KGP156) to the tumor microenvironment. Betabodies are smaller allowing for better tumor penetration compared with previously evaluated PS-selective antibodies, which demonstrated poor distribution beyond the vasculature. BDCs are designed to selectively release KGP18 and KGP156 extracellularly by enzymes (cathepsin B, urokinase-type plasminogen activator, and plasmin) that are upregulated and/or demonstrate enhanced activity by breast cancer cells and associated tumor vasculature. KGP18 and KGP156 are potent inhibitors of tubulin polymerization and demonstrate dual mechanism of action functioning as remarkably active antiproliferative agents (cytotoxicity in low nM to pM range) and as profoundly effective vascular disrupting agents, which impart irreversible damage to tumor-associated vasculature ultimately leading to tumor necrosis. These synthetic benzosuberene-based payloads (KGP18 and KGP156) will be evaluated in comparative studies to monomethyl-auristatin E (MMAE), which is a payload of choice in many clinically relevant antibody-drug conjugates. It should be noted that VDAs are mechanistically distinct from the well-studied angiogenesis inhibiting agents. Two individual delivery strategies will be investigated. KGP18 and KGP156 will be synthetically functionalized with distinct, protease-selective peptide-based linkers rendering the drug-linker prodrug constructs biologically inert until cleaved by specific proteases that are present at high levels in the tumor microenvironment, thus selectively releasing the potent payload (KGP18 or KGP156). In a second strategy, BDCs will be prepared from the best drug-protease selective linker constructs. The hypothesis is that appropriately designed drug-linker constructs and their corresponding BDCs tethered to these highly potent payloads (KGP18 or KGP156) will demonstrate high selectivity for tumor vasculature and tumor cells. Pharmacokinetic studies will evaluate the release of the effector drugs from their corresponding constructs and conjugates. The efficacy and selectivity of these drug-linker constructs and BDCs will be evaluated using cell-based studies and established murine orthotopic breast cancer models (MDA-MB-231 human xenografts and syngeneic 4T1 tumors). In summary, it is expected that each strategy will result in tumor-specific drug delivery and potent anti-tumor activity.
7. 项目总结/文摘

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Structure Guided Design, Synthesis, and Biological Evaluation of Oxetane-Containing Indole Analogues.
含氧杂环丁烷吲哚类似物的结构引导设计、合成和生物学评价。
  • DOI:
    10.1016/j.bmc.2023.117400
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Ren,Wen;Vairin,Rebecca;Ward,JacobD;Francis,Ricardo;VanNatta,Jenny;Bai,Ruoli;Tankoano,PouguiniseliE;Deng,Yuling;Hamel,Ernest;Trawick,MaryLynn;Pinney,KevinG
  • 通讯作者:
    Pinney,KevinG
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rolf A Brekken其他文献

Rolf A Brekken的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rolf A Brekken', 18)}}的其他基金

Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer
靶向磷脂酰丝氨酸的新型蛋白质工程药物缀合物用于治疗乳腺癌
  • 批准号:
    10414970
  • 财政年份:
    2020
  • 资助金额:
    $ 46.63万
  • 项目类别:
Targeted inhibition in stromal TGFβ activity in pancreatic cancer
胰腺癌基质 TGFβ 活性的靶向抑制
  • 批准号:
    10524152
  • 财政年份:
    2020
  • 资助金额:
    $ 46.63万
  • 项目类别:
Targeted inhibition in stromal TGFβ activity in pancreatic cancer
胰腺癌基质 TGFβ 活性的靶向抑制
  • 批准号:
    10210367
  • 财政年份:
    2020
  • 资助金额:
    $ 46.63万
  • 项目类别:
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer
靶向磷脂酰丝氨酸的新型蛋白质工程药物缀合物用于治疗乳腺癌
  • 批准号:
    10183201
  • 财政年份:
    2020
  • 资助金额:
    $ 46.63万
  • 项目类别:
Targeted inhibition in stromal TGFβ activity in pancreatic cancer
胰腺癌基质 TGFβ 活性的靶向抑制
  • 批准号:
    10669058
  • 财政年份:
    2020
  • 资助金额:
    $ 46.63万
  • 项目类别:
Targeted inhibition in stromal TGFβ activity in pancreatic cancer
胰腺癌基质 TGFβ 活性的靶向抑制
  • 批准号:
    10449100
  • 财政年份:
    2020
  • 资助金额:
    $ 46.63万
  • 项目类别:
Murimwa - Targeted inhibition in stromal TGFβ activity in pancreatic cancer
Murimwa - 胰腺癌基质 TGFβ 活性的靶向抑制
  • 批准号:
    10308268
  • 财政年份:
    2020
  • 资助金额:
    $ 46.63万
  • 项目类别:
Exploitation of RAS signaling to develop therapy and early detection strategies for PDA
利用 RAS 信号传导开发 PDA 的治疗和早期检测策略
  • 批准号:
    9012030
  • 财政年份:
    2015
  • 资助金额:
    $ 46.63万
  • 项目类别:
Exploitation of RAS signaling to develop therapy and early detection strategies for PDA
利用 RAS 信号传导开发 PDA 的治疗和早期检测策略
  • 批准号:
    8825835
  • 财政年份:
    2015
  • 资助金额:
    $ 46.63万
  • 项目类别:
Axl as a target for the therapy of pancreatic cancer
Axl 作为胰腺癌治疗靶点
  • 批准号:
    8431020
  • 财政年份:
    2013
  • 资助金额:
    $ 46.63万
  • 项目类别:

相似海外基金

EXCESS: The role of excess topography and peak ground acceleration on earthquake-preconditioning of landslides
过量:过量地形和峰值地面加速度对滑坡地震预处理的作用
  • 批准号:
    NE/Y000080/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.63万
  • 项目类别:
    Research Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328975
  • 财政年份:
    2024
  • 资助金额:
    $ 46.63万
  • 项目类别:
    Continuing Grant
SHINE: Origin and Evolution of Compressible Fluctuations in the Solar Wind and Their Role in Solar Wind Heating and Acceleration
SHINE:太阳风可压缩脉动的起源和演化及其在太阳风加热和加速中的作用
  • 批准号:
    2400967
  • 财政年份:
    2024
  • 资助金额:
    $ 46.63万
  • 项目类别:
    Standard Grant
Market Entry Acceleration of the Murb Wind Turbine into Remote Telecoms Power
默布风力涡轮机加速进入远程电信电力市场
  • 批准号:
    10112700
  • 财政年份:
    2024
  • 资助金额:
    $ 46.63万
  • 项目类别:
    Collaborative R&D
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328973
  • 财政年份:
    2024
  • 资助金额:
    $ 46.63万
  • 项目类别:
    Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328972
  • 财政年份:
    2024
  • 资助金额:
    $ 46.63万
  • 项目类别:
    Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328974
  • 财政年份:
    2024
  • 资助金额:
    $ 46.63万
  • 项目类别:
    Continuing Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
  • 批准号:
    2332916
  • 财政年份:
    2024
  • 资助金额:
    $ 46.63万
  • 项目类别:
    Standard Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
  • 批准号:
    2332917
  • 财政年份:
    2024
  • 资助金额:
    $ 46.63万
  • 项目类别:
    Standard Grant
Study of the Particle Acceleration and Transport in PWN through X-ray Spectro-polarimetry and GeV Gamma-ray Observtions
通过 X 射线光谱偏振法和 GeV 伽马射线观测研究 PWN 中的粒子加速和输运
  • 批准号:
    23H01186
  • 财政年份:
    2023
  • 资助金额:
    $ 46.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了